Table 1

Demographic and clinical data, from 57 kidney allograft recipients (Tx group), 40 uraemic patients (uraemic controls) and 14 healthy controls, at baseline before transplantation.

Tx-group

Uraemic group

Healthy controls

N = 57

N = 40

N = 14


Age (years, SD)

39 ± 13

47 ± 11

39 ± 11

Gender (male/female)

38/19

27/13

5-Sep

ESRD duration (months, range)

24 (0-134)

45 (1-168)

-

BMI (kg/m2)

24 ± 4

24 ± 4

24 ± 3

Waist-hip ratio

0.92 ± 0.09

0.91 ± 0.08

0.81 ± 0.08***

Ever Smoking, n (%)

27 (47)

26 (65)

9 (64)


Diagnoses n (%)

Glomerulonefritis

28 (49)

13 (33)

-

Hypertensive

5 (9)

11 (28)

-

Kidney disease

Vasculitis

1 (2)

1 (3)

-

PKD

3 (5)

7 (18)

-

Other/unknown

20 (35)

8 (20)

-

Apoplexi

3 (5)

3 (8)

-

Former transplanted

11 (19)

10 (25)

-


Dialysis-status

HD

28 (49)

28 (70)

-

CAPD

19 (33)

9 (27)

-

Pre-dialysis

10 (18)

3 (8)

-

First degree relatives with DM

2 (4)

4 (10)

2 (14)

Fasting p-glucose (mmol/L)

5.1 ± 0.5

5.1 ± 0.5

5.0 ± 0.3

P-glucose at 2-hours (mmol/L)

7.4 ± 1

7.5 ± 2

5.4 ± 1***

HbA1c (%)

5.2 ± 0.4

5.2 ± 0.4

5.2 ± 0.2

Insulin sensitivity index

6.8 ± 4.0

7.9 ± 5.1

14.7 ± 7.0***

Insulin secretion index

36.9 ± 18.5

31.4 ± 17.3

27 ± 14

Systolic BP (mmHg)

142 ± 21

141 ± 24

118 ± 10***

Diastolic BP (mmHg)

85 ± 13

83 ± 14

73 ± 8***

Pulse

69 ± 11

72 ± 11

61 ± 10***


Data are presented as mean ± SD or median and range, numbers (n) and percent (%). HD: hemodialysis, CAPD: continuous ambulatory peritoneal dialysis, ESRD: end stage renal disease, Tx: transplantation, PKD: polycystic kidney disease, DM: diabetes mellitus, BP: blood pressure. Wilcoxon Rank Sum Test or two sample t-test used where appropriate to test: uraemic patients vs. Healthy controls; *p < 0.05, **p < 0.005, ***p < 0.0005.

Magnusson et al. BMC Nephrology 2012 13:8   doi:10.1186/1471-2369-13-8

Open Data